Raymond James began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research report sent to investors on Thursday, MarketBeat Ratings reports. The firm issued an outperform rating and a $24.00 price objective on the stock. Dianthus Therapeutics Stock Performance NASDAQ:DNTH opened at $13.67 on Thursday. Dianthus Therapeutics has a 12-month low […]
Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dianthus Therapeutics Launches With $100 Million, Appoints Simrat Randhawa as Chief Medical Officer indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.
Dianthus Launches with $100 Million to Develop Antibody Complement Therapeutics globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.